Type II natural killer T (NKT) cells in cancer immunity are typically associated with suppression of tumor immunosurveillance through secretion of IL-13. We previously demonstrated that CpG oligonucleotide therapy activated Type II NKT cells to produce T helper type 1 (Th1) rather than T helper type 2 (Th2) cytokines. This cytokine skewing may manifest in Type II NKT cell antitumor properties in an immunotherapeutic setting. © 2014 Landes Bioscience.
CITATION STYLE
Zhao, J., Bagchi, S., & Wang, C. R. (2014). Type II natural killer T cells foster the antitumor activity of CpG-oligodeoxynucleotides. OncoImmunology, 3(5). https://doi.org/10.4161/onci.28977
Mendeley helps you to discover research relevant for your work.